论文部分内容阅读
目的分析解毒破瘀汤联合羟基脲治疗慢性粒细胞白血病的效果及不良反应。方法 60例慢性粒细胞白血病患者,随机分为对照组和实验组,各30例。对照组患者实施羟基脲治疗,实验组患者实施解毒破瘀汤联合羟基脉治疗,均随访5年,分析比较两组患者的近期临床疗效、5年生存率及不良反应发生情况。结果对照组患者有效率为80.00%,实验组患者有效率为86.67%,两组有效率比较差异无统计学意义(P>0.05);实验组患者5年生存率为73.33%(22/30),对照组患者5年生存率为36.67%(11/30),实验组患者5年生存率明显高于对照组,差异具有统计学意义(P<0.05);对照组患者不良反应发生率为20.00%(6/30),实验组患者不良反应发生率为3.33%(1/30),对照组患者不良反应发生率明显高于对照组,差异具有统计学意义(P<0.05)。结论对慢性粒细胞白血病患者采取解毒破瘀汤联合羟基脲治疗可有效缓解患者的临床症状,提高患者的5年生存率,且不良反应较少,值得推荐。
Objective To analyze the efficacy and adverse reactions of Jiedu Poyu Decoction combined with hydroxyurea in the treatment of chronic myelogenous leukemia. Methods Sixty patients with chronic myelogenous leukemia were randomly divided into control group and experimental group, with 30 cases in each group. The patients in the control group were treated with hydroxyurea. The patients in the experimental group were treated with Jiedu Poyu Decoction combined with hydroxy-pulse therapy for 5 years. The clinical efficacy, 5-year survival rate and adverse reactions of the two groups were compared and analyzed. Results The effective rate was 80.00% in the control group and 86.67% in the experimental group, with no significant difference between the two groups (P> 0.05). The 5-year survival rate of the experimental group was 73.33% (22/30) . The 5-year survival rate of the control group was 36.67% (11/30). The 5-year survival rate of the experimental group was significantly higher than that of the control group (P <0.05). The incidence of adverse reactions in the control group was 20.00 % (6/30). The incidence of adverse reactions in the experimental group was 3.33% (1/30). The incidence of adverse reactions in the control group was significantly higher than that in the control group (P <0.05). Conclusion The treatment of chronic myeloid leukemia with detoxification decoction combined with hydroxyurea treatment can effectively alleviate the clinical symptoms of patients and improve the 5-year survival rate of patients with less adverse reactions, it is recommended.